SOX₂ Expression in Prostate Cancer Drives Resistance to Nuclear Hormone Receptor Signaling Inhibition through the WEE1/CDK1 Signaling Axis

Investigators reported that NR3C1, the gene encoding glucocorticoid receptor, was a novel sex determining region Y-box 2 (SOX2) target in prostate cancer, positively regulating its expression.